problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl201561556-59problendo-7668Research ArticleОбзорыReviewsВозможности ранней комбинированной терапии сахарного диабета 2-го типаPossible benefits of early combination therapy of type 2 diabetesШестаковаЕкатерина АлексеевнаShestakovaEkaterina Alekseevna

кандидат медицинских наук, научный сотрудник отделения интервенционной кардиологии

MD, PhD

katiashestakova@mail.ruФГБУ «Эндокринологический научный центр» Минздрава РоссииРоссияEndocrinology Research CentreRussian Federation2015141020156155659Copyright © Шестакова Е.А., 20152015Шестакова Е.А.Shestakova E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/7668

Ряд современных алгоритмов терапии сахарного диабета 2 типа предусматривает старт интенсивной сахароснижающей терапии при уровне HbA1c более 7,5% на момент постановки диагноза. Статья рассматривает возможные преимущества комбинированной сахароснижающей терапии в дебюте сахарного диабета 2 типа. 

 

Some current international and national guidelines for type 2 diabetes recommend intensive start of antidiabetic treatment if HbA1c is more than 7.5% at the moment of diagnosis of type 2 diabetes. The article speculates on the possible benefits of combination therapy at the very early stages of type 2 diabetes progression.

сахарный диабет 2-го типакомбинированная терапияtype 2 diabetescombination therapyReferencesДедов И.И., Шестакова М.В., Галстян Г.Р., и др. “Алгоритмы специализированной медицинской помощи больным сахарным диабетом”. Под ред. Дедова И.И., Шестаковой Е.А. (вып. 7-й). //Сахарный диабет. 2015;18:1S:1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (In Russ.)]. doi: 10.14341/dm20151s1-112.Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. “Алгоритмы специализированной медицинской помощи больным сахарным диабетом”. Под ред. Дедова И.И., Шестаковой Е.А. (вып. 7-й). //Сахарный диабет. 2015;18:1S:1-112. [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV. (7th edition). Diabetes mellitus. 2015;18(1S):1-112. (In Russ.)]. doi: 10.14341/dm20151s1-112.Garber AJ, Abrahamson MJ, Barzilay JI, et al. Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438-447. doi: 10.4158/EP15693.CS.Garber AJ, Abrahamson MJ, Barzilay JI, et al. Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21(4):438-447. doi: 10.4158/EP15693.CS.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi: 10.2337/dc14-2441.Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi: 10.2337/dc14-2441.Дедов И.И., Шестакова М.В. “Феномен «метаболической памяти» в прогнозировании сосудистых рисков сахарного диабета”. //Терапевтический архив. 2015; в печати. [Dedov II, Shestakova MV. The phenomenon of «metabolic memory» in predicting cardiovascular risk of diabetes. Ter Arkh. 2015. in press. (In Russ.)].Дедов И.И., Шестакова М.В. “Феномен «метаболической памяти» в прогнозировании сосудистых рисков сахарного диабета”. //Терапевтический архив. 2015; в печати. [Dedov II, Shestakova MV. The phenomenon of «metabolic memory» in predicting cardiovascular risk of diabetes. Ter Arkh. 2015. in press. (In Russ.)].Engel SS, Seck TL, Golm GT, et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocr Pract. 2013;19(5):751-775. doi: 10.4158/EP12436.OR.Engel SS, Seck TL, Golm GT, et al. Assessment of AACE/ACE recommendations for initial dual antihyperglycemic therapy using the fixed-dose combination of sitagliptin and metformin versus metformin. Endocr Pract. 2013;19(5):751-775. doi: 10.4158/EP12436.OR.Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(5):410-417. doi: 10.1111/dom.12233.Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(5):410-417. doi: 10.1111/dom.12233.Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311-1320. doi: 10.1016/S0149-2918(01)80110-7.Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311-1320. doi: 10.1016/S0149-2918(01)80110-7.Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-1168. doi: 10.1185/03007995.2011.570745.Hutchins V, Zhang B, Fleurence RL, et al. A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes. Curr Med Res Opin. 2011;27(6):1157-1168. doi: 10.1185/03007995.2011.570745.Del Prato S, Foley JE, Kothny W, et al. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31(10):1178-1184. doi: 10.1111/dme.12508.Del Prato S, Foley JE, Kothny W, et al. Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial. Diabet Med. 2014;31(10):1178-1184. doi: 10.1111/dme.12508.Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114-1124. doi: 10.1111/j.1463-1326.2008.00875.x.Scherbaum WA, Schweizer A, Mari A, et al. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;10(11):1114-1124. doi: 10.1111/j.1463-1326.2008.00875.x.

The authors declare that there are no conflicts of interest present.